期刊文献+

骨髓瘤RPMI 8226细胞体外逃逸NK细胞免疫杀伤机制的初步研究 被引量:1

Mechanism of immune escape of multiple myeloma cell RPMI 8266 from cytotoxicity of natural killer
原文传递
导出
摘要 目的:探讨骨髓瘤细胞RPMI 8266逃逸NK细胞免疫杀伤的机制。方法:流式细胞仪检测K562和8266细胞表面MICA/B、ULBP1~3和HLA-Ⅰ类分子的表达。4hLDH释放法测定效靶比20∶1时阻断前后NK细胞对2种细胞杀伤活性变化。观察效靶比20∶1时NK细胞对药物处理后RPMI 8226细胞杀伤活性变化、RPMI 8226细胞表面NKG2D配体和HLA-Ⅰ类分子的表达及NK细胞对RPMI 8266细胞的克隆形成率的影响。结果:K562细胞高表达MICA/B和ULBP 1~3分子;RPMI 8266细胞表达HLA-Ⅰ类分子,2株细胞NKG2D配体表达差异有统计学意义,P<0.001。单抗分别阻断MICA/B、ULBP 1~3分子后,效靶比为20∶1时NK细胞对K562细胞的杀伤活性明显降低,P值均<0.05;对RPMI 8266细胞的杀伤活性基本无变化,P值均>0.05。抗W6/32单抗封闭8266细胞表面HLA-Ⅰ类分子后,NK细胞对K562细胞的杀伤活性无上升(P=0.721),而对RPMI 8266细胞的杀伤活性上升,P=0.000。1/2IC50的三氧化二砷处理后RPMI8226细胞ULBP2、3配体升高(P=0.000),NK细胞对8266细胞的杀伤活性与对照组相比差异有统计学意义,P=0.001;1/2IC50硼替佐米处理后RPMI 8226细胞表面各NKG2D配体无变化,P>0.05。NK细胞对K562细胞克隆形成抑制率为(63.48±6.78)%,对RPMI 8226细胞为(23.71±2.39)%,P=0.000。结论:RPMI8266细胞逃逸NK细胞免疫杀伤机制可能与该细胞高表达HLA-Ⅰ类分子,低表达NKG2D的配体MICA/B和ULBP1~3分子有关。 OBJECTIVE:The mechanism of immune escape of multiple myeloma cell line PRMI-8266 from cytotoxicity of natural killer(NK)cell was studied.METHODS:The hypersensitive cell K562 was controlled,after attacked by NK cell at 20∶1,the cytotoxicity of NK cell and proteins expression of NKG2D ligands on K562 and RPMI 8266 cell line was detected by flow cytometry.RPMI 8226 cells was treated by arsenic trioxide and brotezomib(proteasome inhibitor),cytotoxicity of NK cells against pre-treated RPMI 8226 cells at 20∶1 ratio was assayed by LDH releasing kit.Expression of HLA class Ⅰ molecules and NKG2D ligands on the surface of pre-treated RPMI 8226 cells were analyzed by flow cytometry.RESULTS: For K562 cell,MICA/B and ULBP 1-3 were high expressed.There were HLA-Ⅰ moleculer on membrane of RPMI 8266 cell.There were statistical differences between them(P0.001).After blocking MICA,MICB and ULBP 1-3 by mAbs,the Cytotoxicity of NK cells against K562 cell at 20∶1 ratio was much lower than before(P 0.05).But for RPMI 8266,there were no significant difference between before and after blocking experiment(P0.05).But for blocking HLA-Ⅰ,the result were reversely.There was no significant difference of cytotoxity of NK cell against K562 cell between before and after blocking HLA-Ⅰ by W6/32(P=0.721),but for RPMI 8266 it was contrarily(P=0.000).The cytotoxicity of allo-NK cells against RPMI 8226 cells after treated by 1/2 IC50 arsenic trioxide,the expression of ULBP2 and ULBPE were higher than untreated and without the change of HLA-Ⅰ.It was statistically(P=0.001).Cytotoxicity of NK cells against RPMI 8226 cells treated with brotezomib had not affected and no change of NKG2D ligands(P0.05).The inhibiton of clone formation of K562 and RPMI 8226 before and after attacked by Nk cell were(63.48±6.78)% and(23.71±2.39)%(P=0.000).CONCLUSION:Aberrant expression of NKG2D ligand and high expression HLA-Ⅰ molecules may contribute to multiple myeloma cell immune escape from cytotoxicity of NK cell.
出处 《中华肿瘤防治杂志》 CAS 2011年第17期1349-1353,共5页 Chinese Journal of Cancer Prevention and Treatment
关键词 杀伤细胞 天然 多发性骨髓瘤 肿瘤逃逸 keller cells natural multiple myeloma tumor escape
  • 相关文献

参考文献15

  • 1Chen J C,Garba J A.Analyticcl model improvement using model test data[J].AIAA J,1980,18(6):684-690.
  • 2Berman A,Nagy E J.Improvement of a large analytical model using test data[J].AIAA J,1983,21(8):1168-1173.
  • 3Baruch M.Optimal correction of mass and stiffness matrices using measured modes[J].AIAA J,1982,20(11):1623-1626.
  • 4于德介,彭泽民.用广义逆和灵敏度分析修正动力学模型[J].湖南大学学报(自然科学版),1992,19(1):31-36. 被引量:4
  • 5Wai Ming To.Application of singular value decomposition to direct matrix update method[J].AIAA J,1995,32(10):2124-2126.
  • 6Das G, La Rocca R, Lakshmikanth T, et al. Monitoring human leukocyte antigen class I molecules by micro Raman spectroscopy at single-cell level[J]. J Biomed Opt,2010,15(2):027007.
  • 7Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells [J]. Immunol, 2006, 214(1) :130-142.
  • 8Li P, Morris DL, Willcox BE, et al. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like lig- and MICA[J]. Nat Immunol, 2001, 2(5):443-451.
  • 9Casado J G, Pawelec G, Morgado S, et al. Expression of adhe sion molecules and ligands for activating and costimulatory re- ceptors involved in cell mediated cytotoxieity in a large panel of human melanoma cell lines[J]. Cancer Immunol Immunother, 2009,58(9) :1517-1526.
  • 10Stern-Ginossar N, Mandelboim O. An integrated view of the regula- tion of NKG2D ligands[J]. Immunology, 2009,128 (1) : 1-6.

二级参考文献51

  • 1周健,牛新清,梅家转,王杨,涂三芳,何颖芝,周雪云,郭坤元.同种异体NK细胞对不同肿瘤细胞的体外杀伤活性及其机制的初步探讨[J].现代免疫学,2008,28(1):7-11. 被引量:5
  • 2华晓莹,曹祥山,谢晓宝,顾伟英,贺白.小剂量沙利度胺治疗多发性骨髓瘤的临床观察[J].白血病.淋巴瘤,2006,15(5):373-374. 被引量:10
  • 3张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,1999:43-46.
  • 4Suck G. Novel approaches using natural killer cells in cancer therapy[J].Semin Cancer Biol, 2006, 16(5):412-428.
  • 5Zamai L, Ponti C, Mirandola P, et al. NK cells and cancer [J]. J Immunol, 2007, 178(7):4011-4016.
  • 6Bryeeson Y T, Rudd E, Zheng C, et al. Defective eytotoxie lymphocyte degranulation in syntaxin-ll deWcient familial hemophagoeytie lymphohistiocytosis 4 (FHL4) patients [J].Blood, 2007, 110(5):1906 -1915.
  • 7Zhang C, Zhang J, Niu J, et al. Interteukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation[J]. Cytokine, 2008, 42(1):128 -136.
  • 8Hodge D L, Subleski J J, Reynolds D A, et al. The proinflammatory cytokine interleukin-18 alters multiple signaling path ways to inhibit natural killer cell death [J]. J Interferon Cytokine Res, 2006, 26(10):706-718.
  • 9Skak K, Frederiksen K S, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression[J]. Immunology, 2008, 123(4):575- 583.
  • 10Cooper M A, Fehniger T A, Ponnappan A, et al. Interleukin-1βcostimulates interferon-g production by human natural killer cells [J]. EurJ Immunol, 2001, 31(3): 792-801.

共引文献18

同被引文献15

  • 1Palmer JM,Rajasekaran K,Thakar MS. Clinical relevance of natural killer cells following hematopoietic stem cell transplantation[J].J Cancer,2013,(01):25-35.
  • 2Suck G,Koh MB. Emerging natural killer cell immunotherapies:large-scale ex vivo production of highly potent anticancer efec tors[J].Hematol Oncol Stem Cell Ther,2010,(03):135-142.
  • 3Sutlu T,Alici e. Natural killer cell based immunotherapy in cancer:current insights and future prospects[J].{H}JOURNAL OF INTERNAL MEDICINE,2009,(02):154-181.
  • 4Spanholtz J,Preijers F,Tordoir M. Clinical-grade generation of active NK cells from cord blood hcmatopoietic progenitor cells for immunotherapy using a closed-system culture process[J].PLoS One,2011,(06):1-11.
  • 5Berg M,Lundqvist A,McCoy P Jr. Clinical grade ex vivo-expanded human natural killer cells upregulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells[J].{H}CYTOTHERAPY,2009,(03):341-355.
  • 6Mirandola P,Ponti C,Gobbi G,et a 1. The response of human natural killer cells to interleukin-2[J].{H}JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION,2004,(6 Suppl):146-150.
  • 7Dowell AC,Oldham KA,Bhatt RI. Long-term proliferation of functional human NK cells.with conversion oi CD56(dim)NK cells to a CD56 (bright) phenotype,induced by carcinoma cells co-expressing 4-1BBL and IL 12[J].{H}Cancer Immunology lmmunotherapy,2012,(05):615-628.
  • 8Ikemizu S,Chirifu M,Davis SJ. IL2 and IL-15 signaling complexes:different but the same[J].{H}Nature Immunology,2012,(12):1141-1142.
  • 9Herzyk DJ,Bugelski PJ,Hart TK. Preclinical safety of recombinant human interleukin-18[J].{H}Toxicologic Pathology,2003,(05):554-561.
  • 10Konjevic G,Jurisic V,Jovic V. Investigation of NK cell function and their modulation in different malignancies[J].{H}IMMUNOLOGIC RESEARCH,2012,(1-2):139-156.

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部